Completed Date
Sector
Deal Type
Value
Arsal, headquartered in San Salvador, El Salvador, is a leading pharmaceutical manufacturer with over 78 years of experience in the Central American and Caribbean markets. In 2016, Arsal was acquired by Grupo Vargas, a leading regional pharmaceutical player.
BroadSpan Capital acted as exclusive financial advisor to Grupo Vargas and its shareholders on the sale of 100% of the
outstanding shares of Laboratorios Arsal, S.A. to Calox de Costa Rica, S.A. In 2016, Arsal was acquired
by Grupo Vargas, a leading regional pharmaceutical player.
Calox, based in San Jose, Costa Rica, is a pharmaceutical manufacturer with 85 years of experience in
the industry with presence in Central America and the Dominican Republic. Arsal, with its sizeable presence in Central America, backed by a network of distributors and a
dedicated sales force in 8 countries, provides an immediate opportunity for Calox to expand its reach. Arsal has experienced consistent revenue generation stemming from its favorable market share in the regional drug manufacturing market, including several top products across key segments in El Salvador and other geographies.
